Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results

Core Insights - Akeso, Inc. announced long-term survival analysis data for cadonilimab, a treatment for recurrent or metastatic cervical cancer, showing a 100% 24-month overall survival (OS) rate in complete responders [1] - The study highlights cadonilimab's ability to convert deep tumor remission into long-term disease control and survival benefits, providing a new therapeutic option for advanced cervical cancer patients [1] Survival Outcomes - In a study with a median follow-up of 26.5 months, complete responders had a median OS that was not reached, with a 24-month OS rate of 100.0% [1] - For partial responders, the median OS was also not reached, with a 24-month OS rate of 63% and a median progression-free survival (PFS) of 11.17 months [1] - The 12-month PFS rate for complete responders was 84.6%, while for partial responders it was 47.3% [1] PD-L1 Expression Status - The study included over 18% of patients with PD-L1 CPS < 1, demonstrating that cadonilimab achieved a median OS of 17.5 months across the overall population [1] - Updated data showed durable survival benefits with 18-month and 24-month OS rates of 47.8% and 40.9%, respectively, for both PD-L1 positive and negative patients [1] Cadonilimab's Mechanism and Approval - Cadonilimab is the first approved bispecific antibody cancer immunotherapy, launched in 2022, showing superior efficacy in challenging settings like immunotherapy-resistant tumors [1] - The drug targets both PD-1 and CTLA-4, overcoming limitations of existing therapies and is currently approved for three indications in China [1] Clinical Development and Pipeline - Akeso is advancing cadonilimab's global clinical development and is involved in 11 registrational/Phase III studies across various tumor indications [1] - The company has a robust pipeline of over 50 innovative assets, with 26 candidates in clinical trials and 7 new drugs commercially available [1]